NurExone Biologic Inc.
NRXBF
$0.50
-$0.0122-2.38%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -23.68% | 5.66% | -43.71% | -25.10% | 36.30% |
| Total Depreciation and Amortization | 116.67% | 38.46% | -13.33% | 400.00% | -83.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.38% | -1.25% | 1,233.33% | -88.00% | 80.18% |
| Change in Net Operating Assets | -672.45% | -19.67% | 120.96% | -487.88% | -141.42% |
| Cash from Operations | -112.10% | 5.98% | 40.61% | -131.44% | 19.77% |
| Capital Expenditure | 84.72% | -393.44% | 74.69% | -259.70% | -6,800.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Investing | 85.05% | -323.94% | 70.54% | -447.73% | -4,500.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 12.50% | -14.29% | 12.50% | 0.00% | 27.27% |
| Issuance of Common Stock | 66.48% | 5,746.67% | -99.57% | 962.50% | -55.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -427.18% | 983.33% | -96.09% | 500.43% | -170.77% |
| Cash from Financing | -85.94% | 2,761.36% | -99.00% | 4,786.67% | -91.44% |
| Foreign Exchange rate Adjustments | -10,900.00% | -107.41% | 22.73% | 246.67% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,421.01% | 115.86% | -132.06% | 550.83% | -328.90% |